Study: Alzheimer's drug candidate increases levels of beta amyloid

07/17/2009 | Los Angeles Times (tiered subscription model)

A study discovered that Dimebon, a drug candidate for Alzheimer's disease that is currently in Phase III testing, increases the levels of beta amyloid, a marker of the disease, in the brains of animal models. The finding suggests that the benefits of the drug might not be related to beta amyloid levels, a theory that could pave the way for new drug targets in treating the disease.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA